The present invention relates to woven fabrics. More particularly, the present invention relates low profile woven fabrics for implantable medical devices constructed of at least two different materials having different characteristics.
This invention relates generally to medical devices and particularly to medical devices that are implantable within the human or animal body for the repair of damaged vessels, ducts or other physiological passageways and cavities. The physiological passageways and cavities of human and animal bodies, for example, blood vessels and ducts, occasionally weaken or even rupture. One common surgical intervention for weakened, aneurysmal or ruptured passageways or ducts involves the use of an endoluminal prosthesis to provide some or all of the functionality of the original, healthy passageway or duct and/or preserve any remaining vascular integrity by replacing a length of the existing passageway or duct wall that spans the site of failure or defect. Endoluminal prostheses may be of a unitary construction or may be comprised of multiple prosthetic modules.
In one aspect, a woven fabric for a low profile implantable medical device includes a plurality of textile strands of a composite yarn aligned in a first direction interlaced with a plurality of textile strands of the composite yarn aligned in a second direction. The composite yarn includes a combination of a first material and a second material. The textile strands have a size between about 10 denier to about 20 denier. The first material has at least one characteristic different from the second material and the second material reacts favorably with blood when placed within an artery. In some aspects, the textile strands of composite yarn comprise about 50% of the first material by size and about 50% of the second material by size.
In another aspect, a woven fabric suitable for an implantable medical device includes a plurality of textile strands of a composite yarn aligned in a first direction interlaced with a plurality of textile strands of a composite yarn in a second direction. The composite yarn comprises polyester fibers intertwined with polyethylene fibers, the polyester fibers and the polyethylene fibers each having a size of about 10 denier to about 20 denier. The polyester fibers have at least one characteristic different than the polyethylene fibers. In some aspects, the composite yarn is a rope having a central core of polyethylene fibers surrounded by polyester fibers.
In yet another aspect, a method of producing a woven fabric for an implantable medical device is provided. The method comprises providing a plurality of textile strands of a composite yarn to be aligned in a first direction and providing a plurality of textile strands of the composite yarn to be aligned in a second direction. The textile strands are woven together to produce a woven fabric. The textile strands of the composite yarn have a size between about 10 denier to about 20 denier. The composite yarn comprises a combination of a first material and a second material. In some aspects, the weave is a plain weave.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
The term “implantable” refers to an ability of a medical device to be positioned at a location within a body, such as within a body lumen.
The term “strand” as used herein is a generic term for a continuous strand of material suitable for weaving. For example, strands may include, but are not limited to monofilaments, filaments twisted together, fibers spun together or otherwise joined, yarns, roving yarns, crepe yarns, ply yarns, cord yarns, threads, strings, filaments laid together without twist, as well as other configurations.
The term “binding point” refers to the intersection of a single strand in a first direction with strands in a second direction. For example, a strand in a first direction may run “over” one or multiple strands in a second direction, have a binding point, and run “under” one or more subsequent strands in the second direction.
The term “float” refers to that portion of a strand in a first direction that extends over or under two or more strands in a second direction without a binding point. For example, a strand in a first direction may have a binding point with strands in a second direction, then float over 5 adjacent strands in the second direction, then have another binding point with strands in the second direction.
The term “biocompatible” refers to a material that is substantially non-toxic in the in vivo environment of its intended use, and that is not substantially rejected by the patient's physiological system (i.e., is non-antigenic). This can be gauged by the ability of a material to pass the biocompatibility tests set forth in International Standards Organization (ISO) Standard No. 10993 and/or the U.S. Pharmacopeia (USP) 23 and/or the U.S. Food and Drug Administration (FDA) blue book memorandum No. G95-1, entitled “Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part-1: Evaluation and Testing.” Typically, these tests measure a material's toxicity, infectivity, pyrogenicity, irritation potential, reactivity, hemolytic activity, carcinogenicity and/or immunogenicity. A biocompatible structure or material, when introduced into a majority of patients, will not cause a significantly adverse, long-lived or escalating biological reaction or response, and is distinguished from a mild, transient inflammation which typically accompanies surgery or implantation of foreign objects into a living organism.
The term “prosthesis” means any device for insertion or implantation into or replacement for a body part or function of that body part. It may also mean a device that enhances or adds functionality to a physiological system. The term prosthesis may include, for example and without limitation, a stent, stent-graft, filter, valve, balloon, embolization coil, and the like.
The term “endoluminal” refers to or describes the internal or inside of a lumen, duct, and other passageways or cavities located in a human or other animal body. A lumen or a body passageway may be an existing lumen or a lumen created by surgical intervention. As used in this specification, the terms “lumen” or “body passageway,” and “vessel” are intended to have a broad meaning and encompass any duct (e.g., natural or iatrogenic) or cavity within the human body and may include without limitation, blood vessels, respiratory ducts, gastrointestinal ducts, such as the biliary duct, intestines, the esophagus, the pericardial cavity, the thoracic cavity, the pericardial cavity, and the like. Accordingly, the terms “endoluminal device” or “endoluminal prosthesis” describe devices that can be placed inside or moved through any such lumen or duct.
The terms “patient,” “subject,” and “recipient” as used in this application may refer to any animal, particularly humans.
The term “about” used with reference to a quantity includes variations in the recited quantity that are equivalent to the quantity recited, such as an amount that is insubstantially different from a recited quantity for an intended purpose or function.
The term “graft” or “graft material” describes an object, device, or structure that is joined to or that is capable of being joined to or implanted in or against a body part to enhance, repair, or replace a portion or a function of that body part. A graft by itself or with the addition of other elements, such as structural components, may constitute an endoluminal prosthesis. The graft may be comprised of a single material, a blend of materials, a weave, a laminate, or a composite of two or more materials. The graft may also be constructed from a synthetic, for example and without limitation, a polymer. The graft may be formed from a single layer or multiple layers of material. In embodiments employing a plurality of layers of material, the layers may remain separate, or may be attached to each other through a secondary process such as sintering, curing, adhesives, and sutures or the like.
Studies show that, with endovascular grafts, the major component contributing to the volume of the delivery system is the graft material. The present invention relates to low profile woven fabrics for implantable medical devices constructed of composite yarns having at least two different materials having different characteristics. The woven fabric comprising of the composite yarn permits fabrication of a device having a lower profile and is capable of delivery through a low profile delivery device of preferably 12 Fr or less. In one embodiment, the woven fabric comprises weaving textile fibers of a composite yarn in a first direction and a second direction, the composite yarn including low denier polyethylene terephthalate terephthalate fibers, commonly known as PET, with low denier polyethylene fibers. Accordingly, a thin woven fabric is achieved that may be used to provide a low profile, durable, biocompatible endovascular graft having the strength and abrasion resistant characteristics of PE with the high biocompatibility of PET.
As shown in
Accordingly, the first 112 and second material 114 comprising the composite yarn 100 may be chosen such that the sum of each textile strand equals the desired size of the yarn. In some aspects, the composite yarn 110 may range in size from 10 D to 20 D. The size of the first material 112 and the second material 114 forming the composite yarn 100 are desirably formed from low denier textile fibers. In particular, the size of the first material 112 and the second material 114 may range from 5 D to 10 D. In one aspect, the first material 112 comprises polyethylene fibers having a denier of 10 D and the second material 114 comprises polyethylene terephthalate fibers having a denier of 10 D. Thus, the total size of the composite yarn is equal to 20 D. The combination of polyethylene terephthalate fibers and polyethylene fibers provide the woven graft with substantial advantages over conventional graft materials. In particular, the tensile strength of polyethylene allows one to maintain strength characteristics of conventional woven fabric materials in the end product using smaller denier fibers. Further, the composite woven fabric provides geometric advantages by providing the necessary reduction in graft material thickness to achieve smaller delivery system diameters for low profile endovascular graft material. Moreover, the composite woven graft material utilizes the favorable biological response of polyethylene terephthalate as a blood contacting material and subsequent pressure barrier for an endovascular graft.
The spacing of the composite yarn textile strands within the weave is expressed in terms of a linear density or line density of strands, and may depend on the denier of the strands. A higher linear density in indicative of a smaller spacing between adjacent strands. During the weaving process to create the composite woven fabric, the sett and pick count are kept constant. The sett may be between about 50 and about 300 ends per inch and the pick count may be between about 3 and about 500 picks per inch. An “end” refers to an individual warp yarn, and a “pick” refers to an individual weft yarn. In some aspects, the composite woven fabric may consist of a balanced weave (e.g. the composite woven fabric has the same number of weft yarns per inch as warp yarns per inch). In other aspects, the composite woven fabric has an unbalanced weave (e.g. the composite woven fabric has an unequal distribution of warp and weft yarns, with one or the other predominating). For example, a composite woven fabric for producing a prosthesis, such as a stent graft, may comprise a plain weave having 150 ends per inch and 250 picks per inch.
During the weaving process, textile strands woven in the weft direction are subjected to much lower tensile loads than textile strands woven in the warp direction. In some aspects, the combination of strength and abrasion resistance of the first material combined with the favorable blood contacting characteristics of the second material help provide a low profile, high strength, abrasion resistant, biologically compatible graft material. Further, the composite yarns 310, 320 provide the woven fabric 300 with sufficient tensile strength to sustain the tensile loads caused in the warp direction during weaving.
The fabric of the present invention is suitable for use in a variety of implantable or insertable medical devices, for example surgically or endoluminally, of any shape or configuration comprising woven fabric. The medical device may be any device comprising a woven fabric that is introduced temporarily or permanently into the body for the treatment of a medical condition. For example, such medical devices may include, but are not limited to endovascular grafts, stent grafts, balloon catheters, meshes, vascular grafts, stent-graft composites, filters (e.g., vena cava filters), vascular implants, tissue scaffolds, myocardial plugs, valves (e.g., venous valves), various types of dressings, endoluminal prostheses, vascular supports, or other known biocompatible devices.
The medical device may be balloon-expandable or, preferably, self-expanding and may be a bifurcated integrated stent-graft configured for any blood vessel including coronary arteries and peripheral arteries (e.g., renal, superficial femoral, carotid, and the like), a urethral integrated stent-graft, a gastrointestinal integrated stent-graft, or an esophageal integrated stent-graft, for example. Typical subjects (also referred to herein as “patients”) are vertebrate subjects (i.e., members of the subphylum cordata), including, mammals such as cattle, sheep, pigs, goats, horses, dogs, cats and humans.
Throughout this specification various indications have been given as to preferred and alternative embodiments of the invention. However, the foregoing detailed description is to be regarded as illustrative rather than limiting and the invention is not limited to any one of the provided embodiments. It should be understood that it is the appended claims, including all equivalents, that are intended to define the spirit and scope of this invention.
The present application claims priority to U.S. Provisional Patent Application Ser. No. 61/428,580 filed Dec. 30, 2010, the entirety of which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3775961 | Womer | Dec 1973 | A |
3998988 | Shimomai et al. | Dec 1976 | A |
4743250 | Kitagawa et al. | May 1988 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5476506 | Lunn | Dec 1995 | A |
5674276 | Andersen et al. | Oct 1997 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5876432 | Lau et al. | Mar 1999 | A |
5957974 | Thompson et al. | Sep 1999 | A |
6042605 | Martin et al. | Mar 2000 | A |
6155084 | Andrews et al. | Dec 2000 | A |
6187036 | Shaolian et al. | Feb 2001 | B1 |
6364901 | Inoue | Apr 2002 | B1 |
6517572 | Kugler et al. | Feb 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6814754 | Greenhalgh | Nov 2004 | B2 |
6984243 | Dwyer et al. | Jan 2006 | B2 |
7029490 | Grafton et al. | Apr 2006 | B2 |
7121077 | Andrews et al. | Oct 2006 | B2 |
8074436 | Hardee et al. | Dec 2011 | B2 |
20020193820 | Wakuda et al. | Dec 2002 | A1 |
20030023241 | Drewry et al. | Jan 2003 | A1 |
20030028239 | Dong | Feb 2003 | A1 |
20030050666 | Grafton | Mar 2003 | A1 |
20030125796 | Dong | Jul 2003 | A1 |
20030149464 | Dong | Aug 2003 | A1 |
20030204241 | Dong | Oct 2003 | A1 |
20040187471 | Andrews et al. | Sep 2004 | A1 |
20040267313 | Amery et al. | Dec 2004 | A1 |
20050125036 | Roby | Jun 2005 | A1 |
20050159803 | Lad et al. | Jul 2005 | A1 |
20050159804 | Lad et al. | Jul 2005 | A1 |
20050222661 | Case et al. | Oct 2005 | A1 |
20050240261 | Rakos et al. | Oct 2005 | A1 |
20060009835 | Osborne et al. | Jan 2006 | A1 |
20060205308 | Kihara | Sep 2006 | A1 |
20070084182 | Andrews et al. | Apr 2007 | A1 |
20080009903 | Schmieding et al. | Jan 2008 | A1 |
20090024151 | Shalaby et al. | Jan 2009 | A1 |
20090035572 | Hotter et al. | Feb 2009 | A1 |
20090171440 | Carlson et al. | Jul 2009 | A1 |
20090204118 | Pratt | Aug 2009 | A1 |
20110165396 | Norris et al. | Jul 2011 | A1 |
20120168022 | Rasmussen et al. | Jul 2012 | A1 |
Number | Date | Country |
---|---|---|
0128741 | Sep 1987 | EP |
2136858 | Nov 2010 | EP |
1097787 | Jan 1968 | GB |
9932051 | Jul 1999 | WO |
0228314 | Apr 2002 | WO |
2008109019 | Sep 2008 | WO |
2008112242 | Sep 2008 | WO |
2010139340 | Dec 2010 | WO |
Entry |
---|
European Search Report, EP 11275166, filed Dec. 21, 2011, search completed Apr. 17, 2013. |
First Examination Report, AU App. No. 2011265361, report issued Jan. 22, 2013. |
Huijing Zhao et al., “In Vitro Fatigue Properties of Prototype Textile Components of Endovascular Devices”, Fibers and Polymers 2009, vol. 10, No. 1, 91-97. |
Tarng-Jenn yu et al., “Biocomponent vascular grafts consisting of synthetic absorbable fibers. I. In vitro study”, Journal of Biomedical Materials Research, vol. 27, 1329-1339 (1993). |
Extended European Search Report, EP 11275165, filed Dec. 21, 2011, Apr. 24, 2013. |
Australian Patent Examination Report, AU App. No. 2011265360, filed Dec. 20, 2011, Jan. 22, 2013. |
Number | Date | Country | |
---|---|---|---|
20120168022 A1 | Jul 2012 | US |
Number | Date | Country | |
---|---|---|---|
61428580 | Dec 2010 | US |